Induction and treatment of the antiphospholipid syndrome - Lessons from animal models

European Journal of Clinical Investigation

Volumn 31, Issue 8, 2001, Pages 736-740

  Shoenfeld, Y ^a,b   Blank, M ^a,b   Sherer, Y ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Animal model; Anticardiolipin; Antiphospholipid syndrome

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BROMOCRIPTINE; CIPROFLOXACIN; DOPAMINE RECEPTOR STIMULATING AGENT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEPARIN; HYDROXYCHLOROQUINE; IFETROBAN; IMMUNOGLOBULIN; LOW MOLECULAR WEIGHT HEPARIN; PHOSPHOLIPID ANTIBODY; RECOMBINANT INTERLEUKIN 3; THROMBOXANE RECEPTOR BLOCKING AGENT;

ANIMAL MODEL; ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; BONE MARROW TRANSPLANTATION; CONTROLLED STUDY; IMMUNOTHERAPY; MOUSE; NONHUMAN; PREGNANCY; PRIORITY JOURNAL; REVIEW; THROMBOSIS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; ARTERIOSCLEROSIS; AUTOIMMUNE DISEASES OF THE NERVOUS SYSTEM; DISEASE MODELS, ANIMAL; FEMALE; MICE; PREGNANCY; RABBITS; THROMBOSIS;

EID: 0034879015     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.2001.00866.x     Document Type: Review

References (48)

1. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome
2. Phospholipid autoantibodies - Cardiolipin
3. Antiphospholipid syndrome: Insights from animal models
4. IgG anti-cardiolipin antibodies in murine lupus
5. Autoimmune MRL-1pr/1pr mice are an animal model for the secondary antiphospholipid syndrome
6. Anticardiolipin antibodies in NZW x BXSB F1 mice. A model of antiphospholipid syndrome
7. Hemolytic anemia related to an IgM autoantibody to phosphatidylcholine that binds in vitro to stored and to bromelain-treated human erythrocytes
8. Induction of anti-phospholipid syndrome in naive mice with mouse lupus monoclonal and human polyclonal anti-cardiolipin antibodies
9. Lessons from experimental antiphospholipid syndrome (APLS)
10. Monoclonal antiphosphatidylserine antibody induces intrauterine growth retardation in BALB/c mice
11. Induction of antiphospholipid syndrome in naive mice with purifies IgG anti-phosphatidylserine antibodies
12. Induction of experimental primary and secondary antiphospholipid syndromes in naive mice
13. Immunoglobulin G fractions from patients with antiphospholipid antibodies cause fetal death in BALB/c mice: A model for autoimmune fetal loss
14. Specific antiphospholipid antibodies (aPL) eluted from placentae of pregnant women with aPL-positive sera
15. Placental thrombosis and fetal loss after passive transfer of mouse lupus monoclonal or human polyclonal anti-cardiolipin antibodies in pregnant naive BALB/c mice
16. The significance of experimental models of systemic lupus erythematosus and antiphospholipid syndrome induced by idiotypic manipulation
17. Induction of primary antiphospholipid syndrome in mice by immunization with a human monoclonal anticardiolipin antibody (H-3)
18. Antiphospholipid syndrome and the idiotypic network
19. Induction of experimental anti-phospholipid syndrome associated with SLE following immunization with human monoclonal pathogenic anti-DNA idiotype
20. Pathogenic serum IgG anticardiolipin antibodies and the idiotypic network
21. The pathogenic role of anti-phosphatidylserine antibodies: Active immunization with the antibodies leads to the induction of antiphospholipid syndrome
22. Induction of experimental antiphospholipid antibody syndrome in PL/J mice following immunization with beta 2 GPI
23. Early onset of autoimmunity in MRL/++ mice following immunization with β2 glycoprotein
24. Immunization with anticardiolipin cofactor (beta-2-glycoprotein I) induces experimental antiphospholipid syndrome in naive mice
25. Thrombogenic properties of murine anti-cardiolipin antibodies induced by beta 2 glycoprotein 1 and human immunoglobulin G antiphospholipid antibodies
26. Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo
27. GDKV-induced antiphospholipid antibodies enhance thrombosis and activate endothelial cells in vivo and in vitro
28. Neurological dysfunction and hyperactive behavior associated with antiphospholipid antibodies
29. Anticardiolipin antibody aggravates cerebral vasospasm after subarachnoid hemorrhage in rabbits
30. Induction of early atherosclerosis in LDL-receptor-deficient mice immunized with beta2-glycoprotein I
31. Atherosclerosis in LDL-receptor knockout mice is accelerated by immunization with anticardiolipin antibodies
32. The involvement of β2-glycoprotein I (β2-GPI) in human and murine atherosclerosis
33. Oxidized low-density lipoprotein (ox-LDL) but not LDL aggravates the manifestations of experimental antiphospholipid syndrome (APS)
34. Prevention of fetal loss in experimental antiphospholipid syndrome by low-molecular-weight heparin
35. Effect of long-acting thromboxane receptor antagonist (BMS 180,291) on experimental antiphospholipid syndrome
36. The effect of intravenous γ-globulin on the induction of experimental antiphospholipid syndrome
37. Abrogation of experimental systemic lupus erythematosus and primary antiphospholipid syndrome with intravenous gamma globulin
38. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases
39. Prevention of fetal loss in experimental antiphospholipid syndrome by in vivo administration of recombinant interleukin-3
40. Ciprofloxacin immunomodulation of experimental antiphospholipid syndrome associated with elevation of interleukin-3 and granulocyte-macrophage colony-stimulating factor expression
41. Aspirin modulates interleukin-3 production: Additional explanation for the preventive effects of aspirin in antiphospholipid antibody syndrome
42. Transfer of experimental antiphospholipid syndrome by bone marrow cell transplantation
43. Induction of tolerance to experimental anti-phospholipid syndrome (APS) by syngeneic bone marrow cell transplantation
44. Bromocriptine immunomodulation of experimental SLE and primary anti-phospholipid syndrome via induction of nonspecific T suppressor cells
45. Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice
46. Prevention of experimental antiphospholipid syndrome and endothelial cell activation by synthetic peptides
47. Oral tolerance to low dose β2-glycoprotein I. Immunomodulation of experimental antiphospholipid syndrome
48. The antiphospholipid (Hughes') syndrome - An entity to be expanded